← Leaderboards
Shaoyi Jiang
University Of Washington
$3,648,478
Attributed
$3,870,755
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,870,755 · 7
By mechanism
R21$2,159,143 · 5
R01$1,711,612 · 2
Top collaborators
- Nozomi Nishimura1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Janet S Lee$14,899,810
- Owen M Woodward$2,540,894
- Lauren Michelle Schwartz$64,154
- Neil King$14,760,554
Others in their field
Top investigators on “Immunogenicity”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,963,650
- Lawrence Corey · Fred Hutchinson Cancer Center$378,262,806
- Barton F Haynes · Duke University$364,422,244
- Dennis R. Burton · Scripps Research Institute$311,593,259
- Peter B. Gilbert · Fred Hutchinson Cancer Center$200,471,907
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$172,054,560
Research focus
ImmunogenicityCellsTechnologyProteinsPolymersImmune ResponseAntibodiesIn VitroSuccessPropertyCytokineImmunePolyethylene GlycolsNovel StrategiesFormulationIn VivoAdverse EventMembrane ProteinsPerformanceStructureFutureMonitorPeptidesInjections
Grant awards (12)
Immunogenicity of lipid nanoparticles$661,275
R01 · FY2025 · AI · contact PI
Development of Lipid Nanoparticles for Effective Endosomal Escape$392,714
R01 · FY2025 · AI · contact PI
Immunogenicity of lipid nanoparticles$657,623
R01 · FY2024 · AI · contact PI
Reduced Alzheimer's disease progression and neutrophil adhesion via competition using neutrophil-derived or engineered nanoparticles$444,555
R21 · FY2023 · NS
Mitigating the Immunogenicity of Engineered Aav Gene Delivery Vectors by Biomaterial-Driven Immunosuppression$435,412
R21 · FY2023 · EB · contact PI
Zwitterionic Polypeptide-Protein Conjugation for the Safe and Efficient Delivery of Therapeutic Enzymes$129,036
R21 · FY2020 · EB · contact PI
Zwitterionic Polypeptide-protein Conjugation for the Safe and Efficient Delivery of Therapeutic Enzymes$103,421
R21 · FY2020 · EB · contact PI
Minimizing off-target frequency of CRISPR/Cas9 systems via zwitterionic polymer conjugation/peptide fusion$233,250
R21 · FY2019 · GM · contact PI
Zwitterionic Polypeptide-protein Conjugation for the Safe and Efficient Delivery of Therapeutic Enzymes$194,375
R21 · FY2019 · EB · contact PI
Minimizing off-target frequency of CRISPR/Cas9 systems via zwitterionic polymer conjugation/peptide fusion$194,219
R21 · FY2018 · GM · contact PI
Zwitterionic nanogel encapsulation of uricase to evade immune responses$231,750
R21 · FY2016 · EB · contact PI
Zwitterionic nanogel encapsulation of uricase to evade immune responses$193,125
R21 · FY2015 · EB · contact PI